Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026

Metagenomi Therapeutics, Inc.

Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.
FY2024 R&D expense $109.2M (up from $94.4M); G&A expense $32.0M (up from $28.8M).
Hemophilia A program MGX-001: sustained FVIII activity in NHP >16 months; IND submission expected 2026.
Ionis collaboration: four Wave 1 targets in lead optimization; plans to nominate 1-2 DCs in 2025.
Board addition: Eric Bjerkholt (CFO of Mirum Pharmaceuticals) joins audit and compensation committees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.